Adlai Nortye (NASDAQ:ANL) Shares Down 9.1% - What's Next?

Key Points

• Adlai Nortye shares fell 9.1% in midday trading to about $14.19, with trading volume below its average session level.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $29.50, though one firm maintains a sell rating.
• Insiders sold 26,881 shares worth approximately $411,060 over the past 90 days, while institutional ownership stands at 35.21% following several new hedge-fund investments.

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report) shares dropped 9.1% during mid-day trading on Monday. The company traded as low as $14.00 and last traded at $14.1910. 308,137 shares were traded during mid-day trading, a decline of 15% from the average session volume of 363,625 shares. The stock had previously closed at $15.62.

Analysts Set New Price Targets

Several equities analysts have commented on ANL shares. Weiss Ratings reissued a "sell (e+)" rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Cantor Fitzgerald initiated coverage on shares of Adlai Nortye in a research report on Monday, June 22nd. They issued an "overweight" rating on the stock. Loop Capital set a $49.00 price target on shares of Adlai Nortye in a research note on Tuesday, September 8th. Jefferies Financial Group raised shares of Adlai Nortye to a "strong-buy" rating in a research report on Monday, October 5th. Finally, Wall Street Zen raised shares of Adlai Nortye from a "hold" rating to a "buy" rating in a research report on Saturday, October 3rd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $29.50.

Adlai Nortye Stock Performance

The stock has a 50 day simple moving average of $14.57 and a 200-day simple moving average of $12.57.

Insider Buying and Selling at Adlai Nortye

In other news, Director Ping Ji sold 10,000 shares of Adlai Nortye stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $15.99, for a total value of $159,900.00. Following the completion of the transaction, the director owned 121,453 shares of the company's stock, valued at $1,942,033.47. The trade was a 7.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Xiaofeng Ye sold 6,000 shares of the company's stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $13.98, for a total transaction of $83,880.00. Following the completion of the transaction, the chief financial officer owned 153,424 shares in the company, valued at approximately $2,144,867.52. The trade was a 3.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 26,881 shares of company stock valued at $411,060 over the last 90 days.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Braidwell LP purchased a new stake in shares of Adlai Nortye during the second quarter valued at approximately $9,145,000. Boone Capital Management LLC bought a new position in Adlai Nortye in the 2nd quarter valued at approximately $2,971,000. Seven Fleet Capital Management LP purchased a new stake in Adlai Nortye during the 2nd quarter valued at $1,302,000. Affinity Asset Advisors LLC purchased a new stake in Adlai Nortye during the 1st quarter valued at $1,140,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Adlai Nortye during the 1st quarter valued at $816,000. 35.21% of the stock is owned by hedge funds and other institutional investors.

Adlai Nortye Company Profile

Adlai Nortye Ltd. NASDAQ: ANL is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company's research and development programs are centered on immuno-oncology and targeted therapies intended to address unmet medical needs.

Adlai Nortye's pipeline has included buparlisib, an oral pan-PI3K inhibitor being studied in oncology, as well as AN0025, an investigational EP4 antagonist designed to affect pathways involved in tumor growth and immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.